Literature DB >> 19426214

Regulating the regulators: costimulatory signals control the homeostasis and function of regulatory T cells.

Hélène Bour-Jordan1, Jeffrey A Bluestone.   

Abstract

SUMMARY: Costimulation is a concept that goes back to the early 1980s when Lafferty and others hypothesized that cell surface and soluble molecules must exist that are essential for initiating immune responses subsequent to antigen exposure. The explosion in this field of research ensued as over a dozen molecules have been identified to function as second signals following T-cell receptor engagement. By 1994, it seemed clear that the most prominent costimulatory pathway CD28 and functionally related costimulatory molecules, such as CD154, were the major drivers of a positive immune response. Then the immunology world turned upside down. CD28 knockout mice, which were, in most cases, immunodeficient, led to increased autoimmunity when bred into the non-obese diabetic background. Another CD28 family member, cytotoxic T-lymphocyte-associated protein 4, which was presumed to be a costimulatory molecule on activated T cells, turned out to be critical in downregulating immunity. These results, coupled with the vast suppressor cell literature which had been largely rebuked, suggested that the immune system was not poised for response but controlled in such a way that regulation was dominant. Over the last decade, we have learned that these costimulatory molecules play a key role in the now classical CD4(+)CD25(+)Foxp3(+) regulatory T cells (Tregs) that provide critical control of unwanted autoimmune responses. In this review, we discuss the connections between costimulation and Tregs that have changed the costimulation paradigm.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19426214      PMCID: PMC2714548          DOI: 10.1111/j.1600-065X.2009.00775.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  276 in total

1.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

Authors:  S Sakaguchi; N Sakaguchi; M Asano; M Itoh; M Toda
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

2.  CTLA-4 can function as a negative regulator of T cell activation.

Authors:  T L Walunas; D J Lenschow; C Y Bakker; P S Linsley; G J Freeman; J M Green; C B Thompson; J A Bluestone
Journal:  Immunity       Date:  1994-08       Impact factor: 31.745

3.  CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.

Authors:  M F Krummel; J P Allison
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

4.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.

Authors:  E A Tivol; F Borriello; A N Schweitzer; W P Lynch; J A Bluestone; A H Sharpe
Journal:  Immunity       Date:  1995-11       Impact factor: 31.745

5.  Functional LCK Is required for optimal CD28-mediated activation of the TEC family tyrosine kinase EMT/ITK.

Authors:  S Gibson; A August; D Branch; B Dupont; G M Mills
Journal:  J Biol Chem       Date:  1996-03-22       Impact factor: 5.157

6.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

7.  CD28 is associated with and induces the immediate tyrosine phosphorylation and activation of the Tec family kinase ITK/EMT in the human Jurkat leukemic T-cell line.

Authors:  A August; S Gibson; Y Kawakami; T Kawakami; G B Mills; B Dupont
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

8.  CTLA-4 ligation blocks CD28-dependent T cell activation.

Authors:  T L Walunas; C Y Bakker; J A Bluestone
Journal:  J Exp Med       Date:  1996-06-01       Impact factor: 14.307

9.  Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.

Authors:  D J Lenschow; S C Ho; H Sattar; L Rhee; G Gray; N Nabavi; K C Herold; J A Bluestone
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

10.  The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model.

Authors:  N A Hosken; K Shibuya; A W Heath; K M Murphy; A O'Garra
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more
  100 in total

1.  HLA-F is a surface marker on activated lymphocytes.

Authors:  Ni Lee; Akiko Ishitani; Daniel E Geraghty
Journal:  Eur J Immunol       Date:  2010-08       Impact factor: 5.532

Review 2.  Immune checkpoints in central nervous system autoimmunity.

Authors:  Nicole Joller; Anneli Peters; Ana C Anderson; Vijay K Kuchroo
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

3.  Controlled release formulations of IL-2, TGF-β1 and rapamycin for the induction of regulatory T cells.

Authors:  Siddharth Jhunjhunwala; Stephen C Balmert; Giorgio Raimondi; Eefje Dons; Erin E Nichols; Angus W Thomson; Steven R Little
Journal:  J Control Release       Date:  2012-01-21       Impact factor: 9.776

4.  Efficient expansion of cryopreserved CD4(+)CD25(+)CD127(lo/-) cells in Type 1 diabetes.

Authors:  Anna Rydén; Maria Faresjö
Journal:  Results Immunol       Date:  2011-08-22

5.  Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.

Authors:  Charlotte Schwab; Annemarie Gabrysch; Peter Olbrich; Virginia Patiño; Klaus Warnatz; Daniel Wolff; Akihiro Hoshino; Masao Kobayashi; Kohsuke Imai; Masatoshi Takagi; Ingunn Dybedal; Jamanda A Haddock; David M Sansom; Jose M Lucena; Maximilian Seidl; Annette Schmitt-Graeff; Veronika Reiser; Florian Emmerich; Natalie Frede; Alla Bulashevska; Ulrich Salzer; Desirée Schubert; Seiichi Hayakawa; Satoshi Okada; Maria Kanariou; Zeynep Yesim Kucuk; Hugo Chapdelaine; Lenka Petruzelkova; Zdenek Sumnik; Anna Sediva; Mary Slatter; Peter D Arkwright; Andrew Cant; Hanns-Martin Lorenz; Thomas Giese; Vassilios Lougaris; Alessandro Plebani; Christina Price; Kathleen E Sullivan; Michel Moutschen; Jiri Litzman; Tomas Freiberger; Frank L van de Veerdonk; Mike Recher; Michael H Albert; Fabian Hauck; Suranjith Seneviratne; Jana Pachlopnik Schmid; Antonios Kolios; Gary Unglik; Christian Klemann; Carsten Speckmann; Stephan Ehl; Alan Leichtner; Richard Blumberg; Andre Franke; Scott Snapper; Sebastian Zeissig; Charlotte Cunningham-Rundles; Lisa Giulino-Roth; Olivier Elemento; Gregor Dückers; Tim Niehues; Eva Fronkova; Veronika Kanderová; Craig D Platt; Janet Chou; Talal A Chatila; Raif Geha; Elizabeth McDermott; Su Bunn; Monika Kurzai; Ansgar Schulz; Laia Alsina; Ferran Casals; Angela Deyà-Martinez; Sophie Hambleton; Hirokazu Kanegane; Kjetil Taskén; Olaf Neth; Bodo Grimbacher
Journal:  J Allergy Clin Immunol       Date:  2018-05-04       Impact factor: 10.793

6.  Mechanistic Assessment of PD-1H Coinhibitory Receptor-Induced T Cell Tolerance to Allogeneic Antigens.

Authors:  Dallas B Flies; Tomoe Higuchi; Lieping Chen
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

7.  Reduced effectiveness of CD4+Foxp3+ regulatory T cells in CD28-deficient NOD.H-2h4 mice leads to increased severity of spontaneous autoimmune thyroiditis.

Authors:  Jason S Ellis; So-Hee Hong; Habib Zaghouani; Helen Braley-Mullen
Journal:  J Immunol       Date:  2013-10-04       Impact factor: 5.422

8.  New Murine Model of Early Onset Autoimmune Thyroid Disease/Hypothyroidism and Autoimmune Exocrinopathy of the Salivary Gland.

Authors:  Timothy Daniel Kayes; Gary A Weisman; Jean M Camden; Lucas T Woods; Cole Bredehoeft; Edward F Downey; James Cole; Helen Braley-Mullen
Journal:  J Immunol       Date:  2016-08-12       Impact factor: 5.422

9.  Activated CD8+ T cells induce expansion of Vβ5+ regulatory T cells via TNFR2 signaling.

Authors:  Jara J Joedicke; Lara Myers; Aaron B Carmody; Ronald J Messer; Harald Wajant; Karl S Lang; Philipp A Lang; Tak W Mak; Kim J Hasenkrug; Ulf Dittmer
Journal:  J Immunol       Date:  2014-08-06       Impact factor: 5.422

10.  Cutting edge: chronic inflammatory liver disease in mice expressing a CD28-specific ligand.

Authors:  Emily Corse; Rachel A Gottschalk; Joon Seok Park; Manuel A Sepulveda; P'ng Loke; Timothy J Sullivan; Linda K Johnson; James P Allison
Journal:  J Immunol       Date:  2012-12-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.